We have previously shown that the MED-1,2 divergent GATA factors act apparently zygotically to specify the fates of the MS (mesoderm) and E (endoderm) sister cells, born at the 7-cell stage of C. elegans embryogenesis. In the E cell, MED-1,2 activate transcription of the endodermpromoting end-1 and end-3 genes. We demonstrate by in situ hybridization that med transcripts accumulate both in the EMS cell and in the maternal germline in a SKN-1-dependent manner. Removal of zygotic med function alone results in a weakly impenetrant loss of endoderm. However, med-1,2(−) embryos made by mothers in which germline med transcripts have been abrogated by transgene cosuppression fail to make endoderm 50% of the time, similar to the phenotype seen by RNAi. We also find that reduction of Med or End activity results in aberrant numbers of intestinal cells in embryos that make endoderm. We further show that regulation of the paralogous end-1 and end-3 genes consists of both shared and distinct inputs, and that END-3 activates end-1 expression. Our data thus reveal three new properties of C. elegans endoderm specification: both maternal and zygotic activities of the med genes act to specify endoderm, defects in endoderm specification also result in defects in gut cell number, and activation of the paralogous end-1 and end-3 genes differs qualitatively in the relative contributions of their upstream regulators.
Introduction
Embryos have evolved strategies to convert the information encoded in their genomes into a functional organism that resembles its parents. Fundamental among these is the correct spatiotemporal deployment of embryonic genes. Their differential activation is an otherwise unseen indication that qualitative differences exist among cells that display a relatively homogeneous appearance. In the nematode, C. elegans, a network of maternal and zygotic genes acts to assign identities to cells very early in development.
One such gene regulatory network is that which specifies the descendants of the 4-cell-stage blastomere EMS, which divides to produce the founder cells, MS and E, at the 7-cell stage. EMS can be considered to be an endomesoderm precursor, because E will clonally generate the entire endoderm (intestine or gut), while MS makes primarily mesodermal cell types, including body muscle and the posterior half of the pharynx (Sulston et al., 1983) . Specification of MS and E is thought to occur through the sequential activation of a cascade of genes that starts with the maternal factor SKN-1, and proceeds through the activation of the nearly identical paralogous genes med-1 and med-2 in the EMS cell . In turn, MED-1,2 activate the endoderm-specifying genes end-1,3 in E, and are prevented from doing so in MS by the repressive activity of the TCF/LEF homolog POP-1 (Broitman- Lin et al., 1995; . In the E cell, POP-1 is converted into an endoderm activator through the action of the Wnt/MAPK/Src pathway, transduced from a cell-cell interaction that occurs when EMS contacts its neighbor, P 2 (Goldstein, 1992; Lo et al., 2004; Maduro et al., 2005b; Rocheleau et al., 1997 Rocheleau et al., , 1999 Shetty et al., 2005; Developmental Biology 301 (2007) 590 -601 www.elsevier.com/locate/ydbio Thorpe et al., 1997) . In the MS cell, MED-1,2 specify the MS fate primarily by activating the T-box gene tbx-35 (Broitman- Maduro et al., 2006) . Specification of the E fate results from a surprising number of parallel activities that converge on the activation of end-1 and end-3: SKN-1, MED-1,2, Wnt-modified POP-1, and the Caudal homolog PAL-1 all contribute to E specification (Maduro et al., 2005b; Shetty et al., 2005) . Therefore, while descendants of MS are absent in all embryos lacking skn-1 or med-1,2 function, a significant fraction of these (∼30% of skn-1(−) embryos, and ∼50% of med-1,2(−) embryos) still make endoderm (Bowerman et al., 1992; Coroian et al., 2005; Maduro et al., 2001) .
A recent study has challenged the notion that the MEDs are substantially required for endoderm specification (Goszczynski and McGhee, 2005) . In that study, chromosomal med-1,2(−) embryos segregated from a mother carrying med-2(+) were found to specify endoderm between 80% and 97% of the time, contrasting with the 50% we have observed (Coroian et al., 2005; Maduro et al., 2001) . While the most obvious explanation would be that a maternal contribution of the meds accounts for the difference, Goszczynski and McGhee reported that they could find no evidence for maternal med activity. Here we use in situ hybridization to show that the med genes are indeed expressed both maternally and zygotically in C. elegans and in the closely related species C. briggsae. Furthermore, med-1,2(−) embryos lacking both the maternal and zygotic components of med activity display a strong endoderm phenotype. We also find that med-1,2(−) embryos that make endoderm contain an abnormal number of gut cells, and that this phenotype is also a characteristic of skn-1 and end-3 mutants. We extend earlier observations suggesting that end-3 is expressed earlier than end-1 in the E lineage (Baugh et al., 2003) and show that END-3 activates end-1 expression.
Our results validate our original model for C. elegans endoderm specification through med-1,2 and add additional levels of complexity to our understanding of this unexpectedly complex gene regulatory network. These results also suggest that at least some embryonic specification genes are expressed in the C. elegans germ line, working against mechanisms that maintain germ cell totipotency.
Materials and methods

C. elegans strains and genetics
Genetic manipulation and crosses were performed as described (Brenner, 1974) . The following mutations, rearrangements or transgenes were used: LGX: lon-2(e678), and med-1(ok804).
LGIII: dpy-17(e499), sDf127, med-2(cx9744), unc-36(e251), and unc-32(e189).
LGIV: skn-1(zu67).
LGV: dpy-11(e224), end-1(ok558), end-1(ox134), and end-3(ok1448). Free duplications: sDp3(III;f ) [complements dpy-17, sDf127, and unc-36] and irDp1(III;f ) sDf127, . The ok558, ok1448, ok804, and cx9744 lesions are described in Wormbase (http://www.wormbase.org, release WS160; cx9744 is also known as cxTi9744).
The free duplication irDp1 was constructed as follows. BC4638 [dpy-17 sDf127 unc-32; sDp3] hermaphrodites were made transgenic for an array (irEx14) carrying an unc-119::NLS::YFP::lacZ fusion (pMM531), the unc-32-rescuing plasmid pAIE5 (Pujol et al., 2001) , and the med-1(+) plasmid pMM277. Expression of the unc-119 reporter can be followed at all stages beginning in mid-embryogenesis (Maduro and Pilgrim, 1995) . The balancer irDp1 was recovered as spontaneous integrant of irEx14 that had become linked to sDp3, allowing irDp1(+) animals to be identified by unc-119::YFP expression. PCR analysis showed that the med-2 gene remained intact on irDp1. In addition to unc-32 and med-1, irDp1 complements dpy-17, sDf127, and unc-36, suggesting that it contains most of sDp3. To make MS162 [med-1; dpy-17 sDf127 unc-32; irDp1], med-1 males were crossed with lon-2; dpy-17 sDf127 unc-32; irDp1 hermaphrodites, and YFP(+) F 2 descendants were identified that segregated only dead eggs and viable non-Lon YFP(+) animals. Consistent with their being of similar size, irDp1 and sDp3 are inherited by approximately 60% of progeny (data not shown; Hedgecock and Herman, 1995) .
To replace the sDf127 chromosome with med-2(cx9744), med-2 males were crossed to med-1; dpy-17 ncl-1 unc-36 hermaphrodites, and progeny males were then crossed to med-1; dpy-17 ncl-1 unc-36; irDp1. Wild-type F 2 animals from this cross were singled out and the line MS247 [med-1; med-2; irDp1] was one of those that segregated only dead eggs and viable non-DpyUnc YFP(+) animals. PCR analysis showed that MS247 is homozygous for med-1(ok804) and med-2(cx9744). Construction of MS290, a strain derived from MS247 in which irDp1 has been replaced by an array containing the med-1(+) plasmid pMM277 and the unc-119::CFP reporter pMM809, is described in Coroian et al. (2005) . MS290 transmits the med-1(+) array to approximately 45% of progeny. Genotypes were confirmed by PCR where appropriate. Additional strain construction details are available on request.
Microscopy and imaging
An Olympus BX-71 microscope was used for fluorescence and Nomarski microscopy. Images were captured using either a monochrome Microfire CCD or a Canon EOS-350D digital SLR coupled to an LMscope DSLRC adapter (Micro Tech Lab, Austria). GFP, YFP, and CFP were detected using appropriate filter sets (Miller et al., 1999) obtained from Chroma Technology Corp. Images were processed with Adobe Photoshop 7, and figures compiled with Adobe Illustrator CS2.
In situ hybridization
Detection of mRNA in situ was performed as described, using antisense RNA probes of size 0.5 kb-0.8 kb (Coroian et al., 2005) . Freeze-crack permeabilized embryos and hermaphrodites were treated with Streck Tissue Fixative (Streck, Inc.) for 1-2 h at 37°C prior to hybridization. RNA probes were prepared using the Roche DIG RNA labeling kit (#1 175 025) with PCR products tagged on one side with the T7 RNA polymerase recognition sequence. All experiments were performed a minimum of two times with three microscope slides in each experiment. In any given experiment, probe quality and concentration were assayed by staining wild-type animals fixed in parallel, and including only those experiments in which strong staining, with minimal background, was observed in these controls. Both antisense and sense med-1 probes frequently detected weak signal in the anus and pharyngo-intestinal valve, but only antisense med probes detect signal in the gonad, anterior intestine, and early embryo.
RNA interference
RNA interference for skn-1, pal-1, and pop-1 was performed by growing animals on E. coli HT115 bacteria expressing dsRNA (Timmons et al., 2001) .
Results
SKN-1-dependent med expression occurs maternally and zygotically
med-1 and med-2 translational reporter fusions display expression that can be detected in the nuclei of EMS, its daughters MS and E, and their descendants for several divisions (Maduro et al., 2001 ). We performed RNA in situ hybridization using an antisense med-1 probe, which detects both med-1 and med-2 transcripts owing to their 98% sequence identity. We confirmed that embryonic med transcripts do indeed accumulate in the EMS nucleus at the 4-cell stage, become cytoplasmic in MS and E, and are undetectable thereafter (Fig. 1A) (Coroian et al., 2005) . Signal was also observed in the gonads of all adults, with 68% (174/257) showing very strong staining (Fig. 1A) , while very little or no gonadal signal was observed using sense probes (not shown). In the related nematode, C. briggsae, we also found that in situ hybridization with a Cb-med-1 probe reveals gonadal as well as embryonic signal in EMS (Fig. 1H ) (Coroian et al., 2005) . We did not detect significant levels of med transcripts in very early embryos or late oocytes (data not shown). We conclude that med expression has both a maternal and zygotic component, and that both components are evolutionarily conserved.
We compared maternal med expression with that of pal-1, a gene that is also expressed both maternally and zygotically, and which acts to specify the C and D lineages (Baugh et al., 2003; Hunter and Kenyon, 1996) . Gonadal signal detected under similar conditions with a pal-1 probe suggests that maternal med transcripts are significantly less abundant than those of pal-1 (Fig. 1I ). This observation is consistent with results from global microarray experiments, which detected significant germline signal for pal-1 mRNA but not for med-1 (Reinke et al., 2004) . Hence, maternal med transcripts are of relatively low abundance.
The bZIP/homeodomain factor SKN-1 is required for embryonic expression of med transgenes (Bowerman et al., 1993; Maduro et al., 2001 ). Recombinant SKN-1 protein can In parallel experiments, expression is strongly abrogated in the gonads of skn-1(zu67) hermaphrodites and in their progeny. skn-1(RNAi) embryos were similarly absent of zygotic med transcripts. (C) JM134 shows high levels of gonadal med signal similar to wild-type. Embryos carrying sDp3 also express med-2 zygotically. (D) MS162 demonstrates strongly abrogated maternal expression, but zygotic overexpression, due to an integrated med-1(+) transgene on irDp1. (E) Detection of med-2 (in med-1(ok804) animals) shows both maternal and zygotic expression. (F) Detection of med-1 (in med-2(cx9744) animals) shows decreased maternal expression, but normal zygotic expression. (G) An extrachromosomal array providing rescue to a med-1(ok804); med-2(cx9744) strain demonstrates maternal expression and zygotic overexpression. (H) Maternal and zygotic activation of the meds is conserved in the related nematode C. briggsae. (I) Detection of pal-1 mRNA in the gonad and embryos at the 12-cell stage. In N2, pal-1 accumulates stronger signal than med-1 when detected with a similar-sized probe (left panel). At the 12-cell stage, zygotic pal-1 activation is seen in the sister cells C and P 3 . In the absence of med-1,2, an additional expression component appears in MS and E, consistent with the MS, E → C transformation seen in med-1,2(RNAi) (Maduro et al., 2001) . Embryos are shown with the anterior to the left, and dorsal to the top in this and other figures. Scale bars in panel A are 100 μm (adult image) and 10 μm (embryo image).
directly bind SKN-1 sites in the med-1 promoter, and these sites are required for med-1 reporter expression (Blackwell et al., 1994; Maduro et al., 2001) . To assess the requirement of SKN-1 for endogenous med activation, we performed in situ hybridization to detect med transcripts in embryos and adults depleted for skn-1 activity. In the progeny of skn-1(zu67) mothers, or of animals fed skn-1 dsRNA-expressing bacteria, we failed to detect embryonic med transcripts (Fig. 1B and data not shown). Furthermore, while gonadal expression was detectable in skn-1 (zu67)/nT1 animals, the signal was almost undetectable in skn-1 (zu67) homozygotes (Fig. 1B) . We conclude that SKN-1 is required for both maternal and zygotic activation of the med genes.
To determine whether med-1 and med-2 might be differentially regulated, we performed in situ hybridization on strains harboring a mutation in one gene but not the other. The mutation ok804 deletes the entire med-1 locus (Coroian et al., 2005) . Staining of med-1(ok804), which should detect only med-2 transcripts, shows signal in the gonad and embryo that is comparable to that seen in wild-type, with 67% (108/161) of adults showing strong signal (Fig. 1E ). The cx9744 mutation is a Mos1 transposon insertion in the med-2 open reading frame that is predicted to result in production of an aberrant mRNA containing an early nonsense mutation (Coroian et al., 2005) . These aberrant transcripts would be expected to be rapidly degraded by the Smg mRNA surveillance system (Pulak and Anderson, 1993) . Staining of the med-2(cx9744) strain, which should therefore specifically detect only med-1 mRNA, shows a dramatic reduction in the gonad signal: only 15% (25/166) of adults showed staining, and this staining was significantly weaker than in wild-type or med-2(−) (Fig. 1F ). We conclude that while both med-1 and med-2 are activated to roughly similar levels in the 4-cell embryo, med-2 produces more germ line transcripts than med-1. Despite these differences, however, homozygosity for either med allele does not result in an endoderm defect (Table 1) .
Maternal med activity rescues endoderm (E) but not mesoderm (MS) specification
The original assessment of med loss-of-function was based on knockdown of med expression by RNAi. Direct gonadal injection of med-1 dsRNA (which targets both med-1 and med-2) produces arrested progeny embryos, all of which lack posterior pharynx and nearly all PAL-1-independent body wall muscle, tissues normally made by descendants of MS (Maduro et al., 2001; Sulston et al., 1983) . Approximately 50% of these embryos also lack differentiated endoderm. In contrast to these results, Goszczynski and McGhee (2005) reported that 80-97% of embryos chromosomally lacking med-1 and med-2 make endoderm. One strain the authors used to produce med-1,2(−) embryos, JM134, is homozygous for med-1(ok804) and sDf127, a large deletion that removes many genes including med-2 ( Figs. 2A, B) . The lethality of sDf127 in this strain is complemented by the free duplication sDp3, which carries med-2(+). We confirmed that while sDf127 embryos (derived from an sDf127; sDp3 mother) made endoderm 100% of the time (n = 196), 77% of med-1; sDf127 embryos (n = 121) segregated by med-1; sDf127; sDp3 mothers (strain JM134) made endoderm (Figs. 3A, B and Table 1) .
As RNAi can efficiently target maternal as well as zygotic transcripts (Fire et al., 1998) , the simplest explanation for the lower percentage of gutless embryos from the JM134 strain compared to that obtained by med-1,2(RNAi) experiments is that maternal med expression can rescue endoderm. We performed in situ hybridization on JM134 and found that this strain accumulates med transcripts in the gonad similar to wildtype animals, with 75% (57/76) of adults showing strong gonadal staining (Fig. 1C) . Hence, the JM134 strain demonstrates maternal med-2 expression from sDp3.
The presence of gonadal med transcripts in the JM134 strain, whose med-1,2(−) progeny demonstrate a weaker endoderm phenotype than med-1,2(RNAi), suggests that endoderm specification in med-1,2(−) embryos can be partially rescued by maternal med transcripts. We tested this hypothesis by assessing endoderm specification in med-1,2(−) embryos produced by mothers that lack gonadal med transcripts. To deplete maternal med expression reliably, we modified sDp3 to contain an integrated med-1(+) array, generating the free 
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c Segregated from mothers carrying irDp1, which causes knockdown of maternal med transcripts.
d Segregated from mothers carrying irEx138, which provides maternal med(+) activity. duplication irDp1 (Figs. 2A, B) . The presence of this array is predicted to cause depletion of maternal med transcripts by transgene-mediated cosuppression (Dernburg et al., 2000; Robert et al., 2005) . The resultant strain, MS162, has the same genotype as JM134 (i.e. med-1; sDf127) but is balanced by irDp1 instead of sDp3. We performed in situ hybridization on MS162 and found that gonadal med transcripts were undetectable in 99% (69/70) of adults, while embryonic levels were greatly enhanced in EMS (Fig. 1D ). This enhanced expression is consistent with zygotic expression of the repetitive med-1(+) transgene, as a chromosomally integrated med-1:: GFP::MED-1 strain produced a similarly strong EMS signal when stained with an antisense GFP probe (data not shown). We conclude that transgene cosuppression can be used to abrogate endogenous maternal med-2 transcript accumulation, and that this cosuppression does not prevent zygotic activation.
If maternal med expression can rescue endoderm specification in some med-1,2(−) embryos derived from JM134 mothers, then med-1,2(−) embryos produced by MS162, which lacks germline med transcripts, would be predicted to make endoderm less frequently. Indeed, 51% of the med-1,2(−) embryos produced by MS162 lack endoderm (Fig. 3C, Table 1 ), similar to the results we obtained using RNAi (Maduro et al., 2001 ). To rule out any chromosomal differences between JM134 and LGIII containing med-2. sDf127 is a ∼1 MB deletion that removes ∼240 genes including med-2 (http://www.wormbase.org, release WS160). sDp3 is a free duplication that complements sDf127, dpy-17, and a large portion of LGIII to the left (not shown). irDp1 is sDp3 carrying an unmapped integrated array containing med-1(+), unc-32(+) and unc-119::YFP (see Materials and methods). The med-1(+) array causes germline cosuppression of med-2 on irDp1. (B) Production of chromosomally med-1,2(−) embryos in JM134 (Goszczynski and McGhee, 2005) and in MS162, in which sDp3 has been replaced by irDp1. While the JM134 strain has the Unc32 phenotype, MS162 animals are essentially wildtype. (C) Production of med-1,2(−) embryos to test maternal contribution of either med gene. Expected genotype ratios are shown. Abbreviations: m+z−, maternal product supplied, zygotic product absent; m−z−, maternal and zygotic products absent.
MS162, we backcrossed MS162 males to JM134, and mated progeny males back to JM134 repeatedly. We obtained similar results (∼ 50% endoderm defect among med-1,2(−) embryos) after 3× and 10× backcrosses, confirming that the increased severity of the endoderm defect is linked to irDp1, and is not due to a fortuitous background mutation. Replacement of the sDf127 chromosome in MS162 with med-2(cx9744), to create strain MS247, also resulted in a similarly strong endoderm defect ( Table 1) , showing that the increased endoderm defect with irDp1 does not require the loss of other genes deleted by sDf127. We conclude that maternal med-2 expression on sDp3 can rescue endoderm specification in a significant fraction of med-1,2(−) embryos.
To rule out any contribution of the additional genes on the sDp3 or irDp1 balancers used to propagate the med-1; med-2 strains, we replaced irDp1 with an extrachromosomal array containing only med-1(+) and unc-119::CFP, to create MS290 (med-1(ok804); med-2(cx9744); Ex[med-1(+)]) (Coroian et al., 2005) . As the vast majority of arrays in C. elegans do not show germline expression (Kelly et al., 1997) , med-1,2(−) embryos produced by MS290 would not be expected to be maternally rescued for endoderm specification. Unexpectedly, med-1,2(−) embryos segregated from this strain made endoderm 83% (137/165) of the time, suggesting that they were maternally rescued. When we performed med in situ hybridization on MS290, we detected very high levels of gonadal med transcripts (Fig. 1G ). This suggests that intrinsic differences between the med-1(+) array on irDp1 and the extrachromosomal med-1(+) array in MS290 preclude germline transcript accumulation in one case but not the other. Nonetheless, these results provide a further correlation between the presence of germline med transcripts in a mother animal and an increased likelihood that its med-1,2(−) progeny will make endoderm.
As the MS blastomere is also specified by the activity of the meds, we assayed for maternal rescue of the MS defect in med-1 (ok804); med-2(cx9744) embryos. As anticipated by our prior RNAi results, all med-1,2(−) embryos from a mother carrying irDp1 arrest without MS-derived posterior pharynx, as scored both by Nomarski optics and expression of the pharynx muscle marker ceh-22::GFP (Coroian et al., 2005; Okkema and Fire, 1994 ; data not shown). We then examined med-1,2(−) embryos made by MS290 mothers, which provide maternal med(+) activity, and found that 100% of the med-1,2(−) embryos lacked posterior pharynx. Hence, maternal med transcripts produced by a med-1 transgene array cannot rescue MS fate in med-1,2(−) embryos.
To provide a maternal source of med expression from a normal chromosomal context, we constructed animals homozygous for a mutation in one med gene and heterozygous for a mutation in the other, such that 1/4 of the self-progeny are expected to be med-1,2(−) (Fig. 2C) . We found that 26% (190/ 528) of the progeny of med-1/+; med-2 mothers arrested, consistent with expected Mendelian segregation (p = 0.4) and lethality of the med-1; med-2 genotype. However, 42% (332/ 783; p < 10 − 6 compared with expected 1:3) of the progeny of med-1; med-2/+ mothers arrested as embryos. As med-1; +/+ embryos are almost always viable, we compute that approximately 35% of med-1; med-2/+ embryos undergo embryonic arrest due to zygotic haploinsufficiency of med-2 in the absence of med-1. All arrested embryos made from either med-1/+; med-2 mothers or med-1; med-2/+ mothers lacked posterior pharynx as scored by Nomarski optics, confirming that MS fate cannot be rescued by a maternal med(+) gene in its normal chromosomal context. The arrest of 35% of med-1; med-2/+ embryos further suggests that a single zygotic copy of med-2 cannot always rescue MS fate.
We also evaluated rescue of E specification by a single maternal dose of med-1 or med-2. 31% (59/190) of the arrested progeny from med-1/+; med-2 mothers lacked endoderm, while 13% (42/332) of the arrested progeny from med-1; med-2/+ mothers lacked endoderm. Given that 1/4 of the progeny in this latter case are expected to be of the med-1; med-2 genotype, we calculate that a maximum of 21% (42/196) of these lacked endoderm. The 31% [maternal med-1(+)] and 21% [maternal med-2(+)] gutless phenotypes contrast sharply with the~50% of med-1,2(−) embryos that lack endoderm when germline med transcripts are reduced by transgene cosuppression or RNAi. We conclude that a single chromosomal copy of either med-1 or med-2 can maternally rescue specification of E, but not MS, in med-1,2(−) embryos. That more med-1,2(−) embryos are rescued when the mother carries med-2(+) is consistent with the observation that med-2 accumulates more gonadal transcripts than med-1. The differences in gonadal expression and maternal rescue of endoderm suggest that despite 98% sequence identity between the med genes, there are qualitative differences in their contributions to embryonic development. 
Evidence for transport of somatic med transcripts into the gonad
As an alternate approach to preventing med transcripts from being transmitted via the maternal gonad, we obtained med-1,2(−) embryos from mosaic animals that carry med-1(+) gene in the soma, but have a med-1(−) germline. For the strain MS290 (med-1(ok804); med-2(cx9744); Ex[med-1(+)]), such mothers can be recognized because they give rise to a brood consisting entirely of arrested embryos instead of an approximate 1:1 distribution of viable:arrested embryos. From 280 singled MS290 mothers, we obtained 8 (3%) germline mosaics and found, somewhat unexpectedly, that 73% of their progeny (n = 195) contained endoderm. A similar result (73% endoderm, n = 125) was also seen with the progeny from a single germline mosaic med-1(ok804); med-2(cx9744); sDp3 mother. Hence, there is at most only a slight reduction in the degree of maternal med rescue of endoderm when the maternal germline lacks a med(+) gene, rather than a reduction to ∼ 50% as seen with RNAi or when transgene cosuppression is used to abrogate gonadal med transcripts.
One possible explanation for this discrepancy is that somatic med transcripts are imported into the gonad from another tissue. Indeed, we observed that 80% of wild-type adults (n = 45) stained with med-1 antisense probe demonstrated strong expression in the anterior intestine (data not shown). In contrast, only 29% of skn-1(RNAi) animals (n = 42) demonstrated qualitatively similar staining, though at a lower level. In controls using antisense probes for other genes (myo-3, myo-2, and hlh-1), we observed only weak anterior intestine expression in less than 10% of animals (n > 70 for each case). These results suggest that the SKN-1-dependent transcripts found in the adult gonad may result from somatic transcription. This result is further supported by the finding that SKN-1 protein, which activates med expression in the EMS cell, is also present in the intestine (Bowerman et al., 1993) .
med-1 and med-2 are essential for normal E development
The foregoing experiments and our previously published studies have established that while all med-1,2(−) embryos lack cell types made by the MS blastomere, a significantly large proportion of such embryos still make endoderm. As an epitope-tagged med-1::c-myc::MED-1 transgene reveals transgenic MED-1 protein in only the EMS, MS and E nuclei (Maduro et al., 2001) , we wished to investigate whether there might be a role for the meds beyond specification of an endodermal fate.
There is evidence that some med-1,2(RNAi) embryos that make endoderm show defects in early E development. In wildtype embryos, the E daughter cells Ea and Ep migrate into the interior of the embryo at the onset of gastrulation (Sulston et al., 1983) . In some med-1,2(−) embryos, Ea and Ep divide precociously on the ventral surface (Maduro et al., 2001) . Similar defects are also seen in skn-1(zu67) mutant embryos, consistent with the participation of skn-1 and the meds in the same genetic pathway (Bowerman et al., 1992; Maduro et al., 2001 ). When endoderm is not made in med-1,2(−) embryos, the E cell (as with MS in all med-1,2(−) embryos) adopts the fate of its lineal cousin, the mesectodermal precursor C (Maduro et al., 2001) . Specification of C and the ectopic C-like cells made in med-1,2(−) embryos requires maternal activity of the Caudallike homeodomain protein PAL-1 (Hunter and Kenyon, 1996) . In the normal C cell, maternal PAL-1 activates zygotic expression of pal-1, providing an early marker for specification of this lineage (Baugh et al., 2005) .
To test for activation of zygotic pal-1 in med-1,2(−) embryos, we performed pal-1 in situ hybridization on wildtype embryos and those from the MS247 [med-1; med-2; irDp1] strain. pal-1 mRNA was detected in C and P 3 in 87% (26/30) of wild-type embryos showing staining (Fig. 1I) , and at low levels in C, P 3 , MS, and E in the remaining 13%. This suggests that PAL-1 can activate a low level of zygotic pal-1 in a small proportion of MS and E cells. In contrast, 47% (14/30) of stained MS247 progeny showed expression in C and P 3 , and the remaining 53% showed staining in C, P 3 , MS, and E (Fig. 1I) . As the frequency of meiotic loss of irDp1 is approximately 40%, this suggests that the majority of, if not all, med-1,2(−) embryos activate pal-1 in MS and E. We also observed similar ectopic expression of a zygotic pal-1::YFP reporter in med-1,2(−) embryos, suggesting that these pal-1 transcripts do not represent perdurance of maternal message (data not shown). Therefore, many (if not all) of the E cells that ultimately produce gut in med-1,2(−) embryos contain aberrant pal-1 transcripts.
We hypothesized that division and expression defects in the early E lineage may manifest themselves in later embryonic development by altering the pattern of cell divisions in the E lineage. The E cell normally divides 4-5 times to produce 20 cells by the end of embryogenesis (Sulston et al., 1983) . Terminal sDf127 embryos contain a patch of gut granules that comprises ∼25% of the cross-sectional area of the embryo, and which can be seen to be fairly consistent from embryo to embryo (Fig. 3A) . In contrast, many med-1; sDf127 embryos contain gut granule patches that occupy as little as 10% of the area, or consist of only a small number of puncta (Fig. 3B) . We asked whether this reflects a change in the number of gut cells by examining the endoderm in various med-1,2(−) strains using a chromosomally integrated elt-2 reporter transgene to mark intestinal nuclei, as has been used in similar studies of gut cell number Kostic et al., 2003) . A summary of our results is shown in Fig. 4 . As expected, wildtype and single med-1 or med-2 embryos made an average of 20 elt-2-expressing cells with little variation. We found that sDf127 embryos make endoderm with a similar mean number of cells as wild-type, although with a slightly higher variance. The variation was similar in embryos segregated from mothers carrying sDp3 or irDp1, suggesting that the increased variance compared to that in med-2(−) embryos results from loss of other gene(s) in sDf127, rather than from differences in the two free duplications.
Among med-1,2(−) embryos that still made endoderm, the average number of gut cells was reduced, and the variance increased significantly. med-1; sDf127 embryos segregated from mothers carrying either sDp3 or irDp1 showed a combined range of 3-40 gut cells with averages of 14.8 ± 1.2 and 17.3 ± 1.0 cells, respectively. The majority of embryos contained less than 20 cells (67% in the case of sDp3(+) mothers, and 55% for irDp1). med-1,2(−) embryos segregated from irDp1(+) mothers showed a lower mean number (12.0 ± 0.8) and an even higher proportion (81%) of embryos with subnormal numbers of gut cells. We found, overall, that only 10% of med-1,2(−) embryos with any endoderm contain a normal number of 20 gut cells. Thus, 93-95% of med-1,2(−) embryos either make no gut or make a gut that contains abnormal numbers of cells. We conclude, therefore, that med-1 and med-2 are important for normal development of the endoderm in the vast majority of C. elegans embryos.
Distinguishable contributions of end-1 vs. end-3
The paralogous end-1 and end-3 genes appear to function redundantly (Maduro et al., 2005a) . Loss of med-1, med-2, or end-1 individually has no detectable endoderm phenotype, while loss of end-3 results in a weak endoderm specification defect, with approximately 5% of end-3(−) embryos failing to make gut (Table 1) . We tested the ability of mutations in end-1 or end-3 to enhance mutations in the meds (Table 1) . med-1,2(−) embryos lacking the maternal contribution were greatly enhanced for gutlessness by end-1 (only 3% made gut) but not end-3 (37% made gut). In combinations of med and end single mutants, three of the four possible med; end double mutants showed very weak endoderm defects (> 97% made endoderm). The med-1; end-3 double mutant, however, showed strong synergy, as only 42% of embryos made gut. Among those that made endoderm, the number of gut cells made was nearly always abnormal (Fig. 4) . These results show that end-1 and end-3 make different contributions to endoderm specification.
Global transcriptome analysis has suggested that end-3 is activated slightly earlier than end-1 (Baugh et al., 2003) . We performed in situ hybridization to detect end transcripts in wild-type embryos. end-3 mRNA was detected in 84% of embryos at the 1E stage, 63% of 2E stage embryos, and 0% of 4E stage embryos (Figs. 5A, C, E) . end-1 transcripts, by contrast, were detected in 19% of 1E, 90% of 2E, and 83% of 4E stage embryos (Figs. 5B, D, F) . These differences confirm an earlier onset of end-3 activation as compared with end-1. We note that, for both end-1 and end-3 in situ hybridization at the 2E stage, approximately half of the stained embryos showed stronger signal in Ep than in Ea (Figs. 5C, D; discussed below).
We next tested for end activation differences in the absence of the SKN-1 → MED-1,2 pathway by depleting skn-1, a treatment that results in abrogation of both skn-1 and the meds (this work and Maduro et al., 2001 ). In skn-1(RNAi) embryos end-3 mRNA is undetectable, while end-1 is still expressed at high levels (Figs. 6A, C) . We conclude that the early activation of end-3 is accomplished primarily by the activity of SKN-1 → MED-1,2, while end-1 is still activated in their absence.
END-3 and POP-1 activate end-1
Previous experiments established that while the primary role of POP-1 in endoderm specification is the repression of endoderm fate in the MS cell, it also contributes to Wntdependent activation of the endoderm specification pathway in the E cell (Lin et al., 1995; Maduro et al., , 2005b Shetty et al., 2005) . Consistent with this observation, in the absence of end-3, specification of the endoderm becomes largely dependent on POP-1 (Maduro et al., 2005b) . We examined expression of the ends in a pop-1(RNAi) background, and found that transcripts for both genes become detectable to equal levels in the MS and E lineages in a manner that recapitulates their temporal differences in wild-type (Figs. 6B, E) . A repressive role for POP-1 in the Ea cell also became apparent, as >90% of 2E stage pop-1(RNAi) embryos showed equal levels of end-1 expression in Ea and Ep (visible in Fig. 6E) . We have previously shown that transgenic GFP::POP-1 can interact directly with the end-1 and end-3 promoters in vivo at the 2E stage . We conclude that end-1,3 are still responsive to POP-1 in the E daughter cells.
Given the observation that end-3 mRNA accumulates in E earlier than end-1 mRNA, and that an end-3; pop-1 double mutant shows a synergistic defect (only 3% make gut), we hypothesized that END-3 might activate end-1 in parallel with POP-1. There is likely sufficient time for active END-3 to be synthesized from the end-3 mRNA before the E cell divides, as the product of an end-3::c-myc::END-3 fusion transgene can be detected near the end of the E cell cycle (MM and JR, . end-3 is activated earlier than end-1. Detection of transcripts by in situ hybridization is shown for end-3 at the 1E (A), 2E (C), and 4E (E) stages, and end-1 at similar stages in panels B, D, and F respectively. Percentages shown indicate the proportion of embryos of a given stage that showed expression, with total number scored in brackets. Note that in panels C and D, signal is stronger in Ep than in Ea. This was observed in approximately 50% of embryos; symmetrical signal was observed in the remainder. Slides for each probe were prepared from the same batch of embryos. unpublished). In end-3(−) embryos, we found that end-1 mRNA is detectable, though at lower levels than in the wild type (Fig. 6D) . In end-3(ok1448); pop-1(RNAi) embryos, however, expression of end-1 becomes essentially undetectable (Fig. 5F ). We conclude that both POP-1 and END-3 together are essential activators of end-1.
Discussion
A complex network specifies C. elegans endoderm
The advances we have made in this study are as follows: (1) The med genes are expressed maternally in both C. elegans and C. briggsae; (2) Like the zygotic activation of med-1,2, maternal expression requires SKN-1; (3) Endoderm (E) but not mesoderm (MS) fate is partially rescued by this maternal activity; (4) When specification of endoderm is partially compromised, abnormal numbers of intestinal cells are made; (5) med-1 and med-2 make different genetic contributions to E specification, as do end-1 and end-3; (6) end-3 is activated earlier in the E cell cycle than end-1; (7) In addition to acting in parallel with end-1 in promoting endoderm fate, END-3 also activates end-1. Our data reveal new and unexpected complexities in the C. elegans endoderm gene cascade (Fig. 7) .
Maternal deployment of the embryonic SKN-1 → MED-1,2 pathway
We have previously shown that maternally supplied SKN-1 directly activates med-1,2 transgenes in the early EMS lineage, placing med-1,2 downstream of maternal SKN-1. We have shown here that a significant amount of med mRNA accumulates in the hermaphrodite germline, and that this component of med expression also requires SKN-1. Although the med genes are 98% identical within their intronless coding regions and in several hundred base pairs of flanking genomic DNA (Maduro et al., 2001 ), suggesting they are regulated by similar mechanisms, higher levels of maternal med-2 mRNA were detected than for med-1. As med-1 is X-linked, and the X chromosome is specifically underrepresented for genes expressed in the maternal germline (Reinke et al., 2000) , a global X chromosome repression mechanism may act to downregulate maternal med-1 transcription.
We were unable to detect med transcripts above background levels in the very early embryo, even though transcripts for other maternal genes such as skn-1 are detectable this early (Seydoux and Fire, 1994) . One possibility is that a low level of med transcripts in early embryos is simply beyond our ability to detect beyond background signal. Alternatively, some posttranscriptional contribution, such as MED protein, or even end-1,3 mRNA, might be deposited into oocytes. We have seen very weak evidence for a maternal contribution of end-3: 98% of end-3(zu247) embryos (n = 689) derived from an end-3 (zu247)/+ mother made endoderm, while end-3(zu247) embryos from an end-3(zu247) mother made endoderm approximately 94% of the time (n = 518, p < 0.001; MM and JR, unpublished). Regardless of the mechanism, we have shown genetically that the maternal med component is capable of rescuing E specification, but not MS specification, in a fraction of med-1,2(-) progeny embryos.
We have further shown that accumulation of germline transcripts requires SKN-1 function in the mother. As regulation of the meds by SKN-1 is direct in the embryo, maternal activation of the meds is also likely to be direct. While SKN-1 protein has been detected in early embryos, it was not detected in the adult gonad (Bowerman et al., 1993) . This may be because it is below threshold levels for detection. However, our germline mosaic and in situ hybridization data suggest that maternal transcription of the meds may take place outside the germline, perhaps in the intestine, where SKN-1 is also found (Bowerman et al., 1993 ). An intriguing model, then, is that SKN-1 in the soma activates med expression, and these transcripts are somehow transported into the maternal gonad.
What is the purpose of deploying the SKN-1 → MED-1,2 pathway maternally, before it is used embryonically? The activity is clearly weak, as maternal med expression cannot rescue mesoderm specification in the absence of embryonic expression. The pathway that specifies the E fate must be deployed on a relatively short time scale, approximately 20 min (Baugh et al., 2003) . It is possible, therefore, that maternal med activation primes the endoderm specification pathway. Our genetic data show that med activity is particularly critical for activation of end-3, which precedes that of end-1. As end-3 contains four MED binding sites, compared to only two in end-1, end-3 might be more responsive to MED-1,2. Hence, low levels of MED-1,2 in the very early embryo could bind the end-3 promoter and set the stage for activation after E is born.
Accumulation of med transcripts in the germline requires that mechanisms exist to prevent specification of endoderm fate and maintain germ cell totipotency. Translational regulation by the KH-domain proteins MEX-3 and GLD-1 plays a role in blocking somatic differentiation in the germline (Ciosk et al., 2006) . In that study, a small number of germ cells acquired an endoderm fate in mex-1; gld-1 mutants. During the oocyte to embryo transition, the CCCH-type zinc finger OMA-1 is required for oocyte maturation and the blockage of inappropriate activation of cell specification pathways (Shirayama et al., 2006) . It is likely therefore, that multiple mechanisms act to prevent inappropriate specification of endoderm in the germline.
Splitting a redundant gene pair: a new function for END-3
Previous studies indicated that end-3 acts in parallel with end-1 to promote endoderm specification (Maduro et al., 2005a; Zhu et al., 1997) . Null mutations of end-1 showed no endoderm phenotype, while those for end-3 showed a weak defect, suggesting that END-3 makes a stronger contribution to endoderm specification (Maduro et al., 2005a) . Here, we have shown that activation of end-3 is more dependent on the SKN-1 → MED-1,2 pathway than is end-1. Furthermore, we have confirmed earlier findings by others suggesting that end-3 is activated earlier in the E cell cycle than end-1 (Baugh et al., 2003) , and found that end-1 expression is diminished in end-3 (−) embryos and essentially eliminated in end-3(−); pop-1(−) embryos, demonstrating a requirement for both POP-1 and END-3 in end-1 activation. Hence, end-3 mutants show a weak endoderm defect, and end-1 mutants none, because loss of end-3 also affects end-1. It will be of interest to see whether any of these aspects of endoderm specification have been conserved in C. briggsae, which also expresses maternal meds (this work), and which encodes three end-like genes (Maduro et al., 2005a ).
E specification is coupled to the endoderm lineage
We have found that the genes that act to specify the E fate are also important for production of the correct number of gut cells. Mutations in the cell cycle regulators cki-1 and cdc-25.1 result in supernumerary intestinal cells despite correct E specification (Fukuyama et al., 2003; Kostic and Roy, 2002) , suggesting that improper activation of cell cycle regulators accounts for the abnormal gut cell numbers we have observed in embryos that make gut in endoderm-specification mutant backgrounds. It has been proposed that specification of endoderm results from activation of the genes elt-2 and elt-7, which then maintain their expression by positive autoregulation . The wee1 kinase homolog wee-1.1, activated in the E cell, is an apparent target of MED-1,2 (Broitman- Wilson et al., 1999) , and depletion of the ends by RNAi abrogates the expression of intestinal genes (Pauli et al., 2006) . There must therefore be additional roles for the meds and ends in endoderm development in addition to the activation of elt-2,7, or else subtle defects in activation of elt-2,7 may persist into later stages. Whatever the mechanism, correct deployment of the endoderm gene cascade is required for both E specification and normal development of the intestine, suggesting that E specification is not an all-or-none event.
